Morgan Stanley raised the firm’s price target on SI-Bone (SIBN) to $23 from $20 and keeps an Overweight rating on the shares. Going into 2026, MedTech “looks well-positioned on several fronts” as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for “a solid industry setup,” the analyst tells investors in a note for the group on the upcoming year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIBN:
- SI-BONE, Inc. Reports Strong Q3 2025 Earnings
- SI-Bone’s Strong Q3 Performance and Strategic Initiatives Signal Promising Growth and Compelling Buy Opportunity
- SI-Bone’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- SI-Bone’s Strong Financial Performance and Optimistic Future: Buy Rating Affirmed by David Saxon
- SI-BONE, Inc. Reports Strong Q3 2025 Growth